ライフサイエンスコーパス: serum potassium

1 0.83; 95% CI: 0.74, 0.92 per SD increment in serum potassium).

2 ithout significant changes in BP, weight, or serum potassium.

3 and contractile failure correlated with low serum potassium.

4 th sympatho-adrenal activation and a lowered serum potassium.

5 hat occurs in association with a decrease in serum potassium.

6 be nearly normalized by modest elevation of serum potassium.

7 up difference in the adjusted mean change in serum potassium.

8 and <3.5 mmol/L, respectively) and change in serum potassium.

9 a lower risk of diabetes than was low-normal serum potassium.

10 rs, use of antihypertensive medications, and serum potassium.

11 understand how acid-base disturbances affect serum potassium.

12 um (0.44+/-0.14 mmol/L, P=0.02), and lowered serum potassium (0.11+/-0.02 mmol/L, P<0.0001).

13 8.3 to -4.4 mL/min/1.73 m(2)), and increased serum potassium (+0.32 mmol/L; 95% CI: 0.23-0.41 mmol/L)

14 was common (52/104 [50%]), as were abnormal serum potassium (32/97 [33%]), severe hepatitis (54/92 [

15 tween 0 and 15 grams to attain normokalemia [serum potassium 4.0-5.0 mmol/l]) or placebo.

16 . 28.5 +/- 4.2 mm Hg; p < .001), and reduced serum potassium (4.57 +/- 0.22 vs. 5.14 +/- 0.54 mmol/L;

17 boratory-determined hyper- and hypokalaemia (serum potassium 6.0 and <3.5 mmol/L, respectively) and c

18 Six participants had increases in serum potassium above 6.0 mmol/L that corrected with dos

19 normal axonal resting potentials had normal serum potassium, although urea and creatinine were eleva

20 y but significant and persistent (1) rise in serum potassium and (2) reduction in estimated glomerula

21 , we found a significant interaction between serum potassium and aldosterone (P = 0.046).

22 s index, net endogenous acid production, and serum potassium and bicarbonate), hazard ratios of the c

23 Thus, T2D may causally affect serum potassium and chloride levels among East Asians.

24 it from candesartan, careful surveillance of serum potassium and creatinine is particularly important

25 mg once daily with recommended monitoring of serum potassium and creatinine.

26 In both groups, short-term increases in serum potassium and decreases in eGFR were associated wi

27 The changes in serum potassium and estimated glomerular filtration rate

28 Hypothermic rats had lower serum potassium and higher blood glucose concentrations

29 ne concentrations were associated with lower serum potassium and higher urinary excretion of potassiu

30 we found no significant association between serum potassium and incident diabetes.

31 dosterone may modify the association between serum potassium and incident diabetes.

32 Aldosterone affects serum potassium and is associated with insulin resistanc

33 y standpoint, salt substitute increased mean serum potassium and led to more frequent biochemical hyp

34 t with FBS, dapagliflozin was safe, improved serum potassium and phosphate concentrations, and reduce

35 nal incidentaloma; additional measurement of serum potassium and plasma aldosterone concentration-pla

36 Additionally, age, PTT, serum potassium and temperature were associated with pre

37 en aldosterone and MR activity, assessed via serum potassium and urinary fractional excretion of pota

38 ICU length of stay, hospital length of stay, serum potassium, and blood urea nitrogen as key contribu

39 e guidelines recommend routine monitoring of serum potassium, and renal function in patients treated

40 inine, estimated glomerular filtration rate, serum potassium, and systolic blood pressure.

41 Racial differences in serum potassium appeared to explain 18% of the excess ri

42 Low serum potassium appears to be independently associated w

43 tors of severe AKI were CKD, men, and higher serum potassium at admission.

44 The serum potassium AUC increased with the dose (P < 0.0001)

45 ta [SE], 0.065 [0.015]; P < .001), but lower serum potassium (beta [SE], -0.073 [0.022]; P < .001).

46 62.5% of patients; severe hyperkalemia (peak serum potassium concentration > or = 5.5 mmol/L) occurre

47 ARBs) may increase the risk of hyperkalemia (serum potassium concentration >5 mmol/L) in the setting

48 nine ratio (UACR) of >100-<=5000 mg/g, and a serum potassium concentration 3.5-5.0 mmol/L were random

49 showed that in patients with hyperkalemia (serum potassium concentration 5.10-6.50 mmol/l [5.1-6.5

50 AFACS prophylaxis, supplementation only when serum potassium concentration fell below 3.6 mEq/L was n

51 xed potassium control (only supplementing if serum potassium concentration fell below 4.5 mEq/L or 3.

52 The steady-state serum potassium concentration frequently changes during

53 A peak serum potassium concentration greater than 5.0 mmol/L de

54 ice of supplementing potassium to maintain a serum potassium concentration greater than or equal to 4

55 cathartic, but the effect of such therapy on serum potassium concentration has not been established.

56 he effect of increasing dietary potassium on serum potassium concentration in hypertensive individual

57 The serum potassium concentration in the control group was 4

58 The serum potassium concentration in the treatment group (me

59 Serum potassium concentration increased from 3.0 mmol/L

60 On placebo therapy, the average serum potassium concentration increased slightly (0.4 mE

61 Fecal potassium output and serum potassium concentration were measured for 12 h.

62 Serum potassium concentration, 3-d food records, and 24-

63 py produces no or only trivial reductions in serum potassium concentration, and because this therapy

64 lator therapy was independent of the initial serum potassium concentration.

65 a variety of medications that can alter the serum potassium concentration.

66 ith structural heart disease and an abnormal serum potassium concentration.

67 le option for controlling blood pressure and serum potassium concentration.

68 t various infections leads to an increase in serum potassium concentration.

69 apical membrane region over a wide range in serum potassium concentration.

70 gimens were associated with a slight rise in serum potassium concentrations (similar to placebo); thi

71 he treatment and control groups had the same serum potassium concentrations and did not receive diffe

72 Mean serum potassium concentrations decreased from 4.9 mmol/L

73 increased potassium intake in the HKD group, serum potassium concentrations did not significantly inc

74 Low serum potassium concentrations in African Americans may

75 Whether interventions to increase serum potassium concentrations in African Americans migh

76 yperkalemia as >=mild or >=moderate based on serum potassium concentrations of >5.5 or >6.0 mmol/L, r

77 ed hyperkalemia as mild or moderate based on serum potassium concentrations of >5.5 or >6.0 mmol/L, r

78 (95% CI) of incident diabetes for those with serum potassium concentrations of <4.0, 4.0-4.4, and 4.5

79 of the study, when clinically indicated, for serum potassium concentrations of 3.5 mmol/L or serum ma

80 and 4.5-4.9 mEq/L, compared with those with serum potassium concentrations of 5.0-5.5 mEq/L (referen

81 Mean serum potassium concentrations were lower in African Ame

82 lectrolyte abnormalities, including abnormal serum potassium concentrations, are considered a correct

83 None of the regimens reduced serum potassium concentrations, compared with baseline l

84 ed hypertension are now known to have normal serum potassium concentrations.

85 We hypothesized that low serum potassium contributes to the excess risk of diabet

86 cardiovascular outcomes despite efficacy on serum potassium control.

87 ry composite end point, and those reflecting serum potassium control.

88 An increase in serum potassium corrects abnormalities of repolarization

89 The increases in serum potassium did not translate into increased cardiac

90 Hs) of incident diabetes related to baseline serum potassium during 9 y of follow-up.

91 he 285 patients who received spironolactone, serum potassium exceeded 6.0 mmol/L on one occasion.

92 ons were associated with a lower eGFR, lower serum potassium, greater urinary potassium, and protein

93 losilicate in outpatients with hyperkalemia (serum potassium >/=5.1 mEq/L) recruited from 44 sites in

94 primary outcome was new-onset hyperkalaemia (serum potassium >5.5 mmol/L).

95 mia rates regardless of the definition used (serum potassium >5.5 mmol/l: 8.6% vs. 9.9%, HR 0.85, 95%

96 but the incidence of serious hyperkalaemia (serum potassium >6.0 mmol/L) was low (2.9% vs 1.4%); the

97 9.9%, HR 0.85, 95% CI 0.74-0.97, P = 0.017; serum potassium >6.0 mmol/l: 1.9% vs. 2.9%, HR 0.62, 95%

98 % CI: 0.23-0.41 mmol/L) and the frequency of serum potassium (>5.5 mmol/L: 5 [4.8%] vs 1 [0.9%]).

99 ient-reported hypoglycemia and hyperkalemia (serum potassium>5.5 mEq/L), respectively.

100 At baseline, the mean serum potassium in canagliflozin and placebo arms was 4.

101 ological ionic strength, and (3) response to serum potassium in the presence of fouling biological co

102 xercise, and atrial pacing, before and after serum potassium increase.

103 ho received placebo, urine potassium but not serum potassium increased significantly among participan

104 d with taurolidine, hydrogen peroxide, human serum, potassium iodide and doxorubicin/ oxaliplatin for

105 l studies are warranted to determine whether serum potassium is a modifiable risk factor that could b

106 ing of blood pressure, serum creatinine, and serum potassium is warranted.

107 xamined the relationship between eplerenone, serum potassium (K(+)), and clinical outcomes in the Epl

108 Guidelines recommend measurement of serum potassium (K) and creatinine (Cr) before and seria

109 ronounced in patients with lower predialysis serum potassium (K) levels (HR 2.53 [P = 0.01] for K <4.

110 asting hours to days associated with reduced serum potassium (K+).

111 iltration rate, 15 to <60 mL/min/1.73 m2 and serum potassium level >5.0 mEq/L).

112 s and were categorized by mean postadmission serum potassium level (<3.0, 3.0-<3.5, 3.5-<4.0, 4.0-<4.

113 tiromer was titrated to achieve and maintain serum potassium level 5.0 mEq/L or lower.

114 ed in statistically significant decreases in serum potassium level after 4 weeks of treatment, lastin

115 aped relationship between mean postadmission serum potassium level and in-hospital mortality that per

116 o investigate the impact of patiromer on the serum potassium level and its ability to enable specifie

117 he association between abnormal preoperative serum potassium level and perioperative adverse events s

118 lamines, and, in the hypertensive patient, a serum potassium level and plasma aldosterone concentrati

119 s the exponential rate of change in the mean serum potassium level at 48 hours.

120 east squares mean reduction from baseline in serum potassium level at week 4 or time of first dose ti

121 d the need for CPR increased as preoperative serum potassium level decreased below 3.5 mmol/L.

122 tion of kidney replacement therapy, the mean serum potassium level decreased from 5.1 0.9 to 4.5 0.7

123 y outcome was the mean absolute reduction in serum potassium level from baseline at 3 distinct time i

124 rimary efficacy end point was mean change in serum potassium level from baseline to week 4 or prior t

125 fficacy end point was the mean change in the serum potassium level from baseline to week 4.

126 At 48 hours, the mean serum potassium level had decreased from 5.3 mmol per li

127 The primary end point was mean serum potassium level in each zirconium cyclosilicate gr

128 Patients were stratified by baseline serum potassium level into mild or moderate hyperkalemia

129 sociation between increased need for CPR and serum potassium level less than 3.3 mmol/L (OR, 3.3; 95%

130 Serum potassium level less than 3.5 mmol/L was a predict

131 group difference in the median change in the serum potassium level over the first 4 weeks of that pha

132 efficacy end points included mean change in serum potassium level through 52 weeks.

133 after day 3, the mean (+/-SE) change in the serum potassium level was -1.01+/-0.03 mmol per liter (P

134 Her serum potassium level was 13.1 mEq/L and HCO3- was 16 mE

135 The mean (SD) baseline serum potassium level was 5.60 (0.35) mEq/L (to convert

136 Serum potassium level was measured at every study visit.

137 Serum potassium level was significantly higher with the

138 Hypokalemia (low serum potassium level) is a common electrolyte imbalance

139 he proportion of patients with hyperkalemia (serum potassium level, >/=6 mmol per liter) was signific

140 Hyperkalemia (serum potassium level, >5.0 mmol per liter) is associate

141 Patients with normokalemia (serum potassium level, 3.5 to 4.9 mmol per liter) at 48

142 CT images, aldosterone-to-renin ratio (ARR), serum potassium level, and blood pressure control were a

143 ondary outcomes were hyperkalemia defined as serum potassium levels >=5.5 mmol/L and hyperkalemia dia

144 High serum potassium levels (> 5.4 mmol/L) were associated wi

145 Spironolactone also modestly increased serum potassium levels (+0.2 mmol/L; 95% CI, +0.1 to +0.

146 demonstrated smaller percentage increases in serum potassium levels (as determined by %AUC; 4.3+/-6.8

147 trumented associations of T2D with increased serum potassium levels (liability-scale beta = 0.04-0.10

148 as associated with a significant decrease in serum potassium levels and a low incidence of hypokalemi

149 Safety was established through serial serum potassium levels and measurement of cystatin C, a

150 treatment was associated with a decrease in serum potassium levels and, as compared with placebo, a

151 bined) included 9583 patients with available serum potassium levels at baseline (98.6% of the total E

152 ity was observed in those with postadmission serum potassium levels between 3.5 and <4.5 mEq/L compar

153 al practice guidelines recommend maintaining serum potassium levels between 4.0 and 5.0 mEq/L in pati

154 In the open-label phase, serum potassium levels declined from 5.6 mEq/L at baseli

155 ither modeled continuously or categorically, serum potassium levels during long-term monitoring were

156 During the study, serum potassium levels guided drug dosing.

157 ovel selective cation exchanger, could lower serum potassium levels in patients with hyperkalemia.

158 of administering patiromer for reduction of serum potassium levels in this setting is unknown.

159 Mean serum potassium levels increased from 2.6 mmol/L +/- 0.4

160 o were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to less than 6.5 mmol per

161 patient or emergency department setting, and serum potassium levels of 5.5 mmol/L or more.

162 yclosilicate, used to treat and prevent high serum potassium levels on a more chronic basis, have spa

163 Serum potassium levels rise substantially during vigorou

164 of ZS-9 and those who received 10 g of ZS-9, serum potassium levels were maintained at 4.7 mmol per l

165 statistically significant mean decreases in serum potassium levels were observed at each monthly poi

166 the hemodialysis prescription is to maintain serum potassium levels within a narrow normal range duri

167 itable, and which may be precipitated by low serum potassium levels.

168 higher blood pressure, kaliuresis, and lower serum potassium levels.

169 factors for >=mild hyperkalemia were higher serum potassium, lower eGFR, increased urine albumin-cre

170 sk factors for mild hyperkalemia were higher serum potassium, lower eGFR, increased urine albumin-cre

171 ce of hypokalaemia (investigator-reported or serum potassium <3.0 mmol/l) was not significantly incre

172 tration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.

173 nal screening visit were stratified by local serum potassium measurement (4.3 to <4.7 mmol/L vs 4.7 t

174 All patients had in-hospital serum potassium measurements and were categorized by mea

175 There were 13 abnormal serum potassium measurements in 1802 measurements obtain

176 hange in practice will require more frequent serum potassium monitoring and responsive dialysis care

177 s, as well as with interventions to increase serum potassium more than was achieved with our interven

178 ryngeal temperature of 13.8 degrees C, and a serum potassium of 11.3 mmol/L.

179 io (UACR) of 200 to less than 5000 mg/g, and serum potassium of 4.8 mmol/L or less, taking an angiote

180 study outcome was hyperkalemia, defined as a serum potassium of greater than 5.5 mEq/L or an administ

181 laboratory values, and 34% did not have any serum potassium or creatinine determined within three mo

182 between short-term post-baseline changes in serum potassium or eGFR and subsequent hyperkalemia risk

183 ve in identifying therapy-related changes in serum potassium or kidney function.

184 icant changes in heart rate, blood pressure, serum potassium, or renal function were observed.

185 over the study period for serum bicarbonate, serum potassium, or urine chloride end points.

186 The mean serum potassium over time with canagliflozin was similar

187 ter propensity score matching (PSM) for age, serum potassium, pH, bicarbonate, and P co2 level.

188 een serum posaconazole levels and changes in serum potassium (r = -.39, P = .006), and a positive cor

189 he former, superexcitability correlated with serum potassium (R = 0.88), and late subexcitability was

190 een serum posaconazole levels and changes in serum potassium (r =-.39, P=0.006), and a positive corre

191 ity parameters correlated significantly with serum potassium (range 4.3-6.1 mM), but not with other m

192 ssible in children with body temperature and serum potassium reaching the far limits of previously re

193 articularly increased blood pressure and low serum potassium) related to the stimulation of aldostero

194 ihypertensive medication, diabetes mellitus, serum potassium, serum albumin, high-density lipoprotein

195 Of all the electrolytes, serum potassium showed the most significant associations

196 , KCl at a dose of 40 mEq/d did not increase serum potassium significantly.

197 The optimal approach towards managing serum potassium (sK(+)) and hemodialysate potassium conc

198 elines recommend routine kidney function and serum potassium testing within 30 days of initiating ACE

199 oncentrations supports the practice of using serum potassium to guide potassium replacement in patien

200 label sodium zirconium cyclosilicate reduced serum potassium to normal levels within 48 hours; compar

201 y and had lower levels of plasma glucose and serum potassium upon oral glucose stimulation and increa

202 e was prescribed to 22.8% of patients with a serum potassium value > or =5.0 mmol/L, to 14.1% with a

203 ports of adverse events, and by a laboratory serum potassium value above 5.5 mmol/L and 6.0 mmol/L.

204 (RR, 2.75; 95% CI, 2.14-3.52) or an abnormal serum potassium value if they were aged >/=76 years (RR,

205 sought to determine the association between serum potassium values collected at follow-up with all-c

206 Despite the same serum potassium values, the net potassium balance for 48

207 perkalemia had the study drug withheld until serum potassium was <=5.0 mmol/L; then the drug was rest

208 perkalemia had the study drug withheld until serum potassium was 5.0 mmol/L; then the drug was restar

209 hemodialysis with predialysis hyperkalemia (serum potassium was 5.5 mmol/l or more) were randomized

210 In a minimally adjusted model, serum potassium was a significant predictor of incident

211 cipants with normal aldosterone, high-normal serum potassium was associated with a lower risk of diab

212 egion and pendrin abundance per cell whether serum potassium was high or low.

213 Serum potassium was measured at every physician-patient

214 In the randomized phase, serum potassium was significantly lower during days 8-29

215 estimated glomerular filtration rate and in serum potassium were available in 2737 patients during a

216 of nonsustained ventricular tachycardia, and serum potassium were related to sudden cardiac death.

217 The multivariable-adjusted association of serum potassium with mortality was assessed by using com

218 -concordant testing for serum creatinine and serum potassium within 180 days before or 14 days after

219 We hypothesized that an increase in serum potassium would normalize repolarization in these